Clinical Research Directory

Inclusion Criteria: 1. Patients with a clear diagnosis of atopic dermatitis in accordance with the diagnostic criteria of Chinese and Western medicine; 2. Age ≥2 years and ≤75 years; gender is not limited; 3. Patients with a previous history of moderate to severe atopic dermatitis (EASI score ≥ 8, or SCORAD score ≥ 26, or IGA score ≥ 3); 4. Patients were in AD remission with a skin lesion IGA score ≤ 1 for 2 consecutive weeks; 5. All patients or guardians signed an informed consent form, of which the guardian signed the informed consent form for patients aged 2-8 years (\<8); the patient and guardian signed the informed consent form for patients aged 8-18 years (\<18); and the patient signed the informed consent form for patients aged 18-75 years. Exclusion Criteria: 1. Patients who are in the acute morbid stage and have erosion, exudation, and secondary infection; 2. Patients who are allergic to the test article and its components; 3. Patients who are currently participating in other clinical studies or have participated in other clinical studies within 1 month; 4. Patients with skin diseases other than AD in the area to be treated; 5. Patients with severe hepatic or renal diseases, hematologic disorders, autoimmune diseases, chronic severe infections, diabetes or diseases of God, drug or alcohol abuse; 6. Suffering from malignant tumors or other serious diseases that may affect the correct assessment of efficacy; 7. Have been treated with dupliyuzumab with a discontinuation time ≤ 12 weeks, or have been treated with a JAK inhibitor with a discontinuation time ≤ 1 week; 8. Patients who have been systematically treated with hormones, other immunosuppressive agents (cyclosporine, methotrexate, reglanoside, etc.) or phototherapy; 9. Other reasons (e.g., poor compliance, inability to follow up as scheduled) that the investigator believes preclude enrollment.